{"ticker": {"uuid": "b546482b-c0b2-48b3-b57b-81ca2d16e710", "symbol": "AGEN", "name": "Agenus Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOeXlIYmdZUE5ETktrRU4wMVFkcXRzTkxGN2o2SmpyeC1JZW52dWxqUFNTTFFfV0VDUUFxZ3lnRGtEMF9BNF93bXZIajB1T1RNNWFRQ1hXMVBKcEtTR0VnaVJUOWVGY2JKZHozc1NhVUtoVk9OMXRXdVpvaDZ6ZWNOT19YcWNyVkNBckxQUWY2ZkFjWm1pWjBLUlA2SmdpUlN6VnNpbmtpcTJQcjJRcjg3TkFWWUs3WEdUMzFKOWlkZ1dvQ1pjeVp0TXVaTTNKaERsMy04b2lLUdIB3AFBVV95cUxPcldYckhTM2psUklLaVZzVUdnMDFNbnIxR1JidGFUOEFucFdiYVZHWDNqMGpqRDFScVpLNFpTTlFMRk8zUEU5cGgyZFQ3dEIza1MweXcyWGNNSFRwSV9LWDZkb3pNZGxYMGJrQmFvcms0YnF2ZUFOSG9IZHZpbGZKNkZSbDZWZWJzOFh4ZHhkbnQtNmZHZXd1b0gzOXJPVmptWjRoVzFOTk5UaDBKSzh3VUlvQm5VRURZdzRTUHZjSjJBTlYtUTVrUmo4Qlo4dklVZlRpd2lJVmQtTlZ6?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T13:37:29+00:00", "published_display": "15 Jul 2026 13:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPTkRWSVFKZTJFRnhHaEhWbXc0NEpYaDRsZ25vckViQ09sSEQtSXc1bnRyUnY2bVo2M055SmlDdGV4UUhDTFBNN2RyY1B2ZzlvUWV1V2V3dFVtYlBaQkdtUUI4LVpWVjBoa0dJZFpPY0dieTBiVmNEVUZmTVVrd2VCZTNoUENPbk1RVjNEZ1pDOV96WlQwTjhJM0hubEJ1OWtWa2xESnZIZU8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T12:04:17+00:00", "published_display": "15 Jul 2026 12:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Inc. (NASDAQ: AGEN) director takes 4,852-share stock salary grant", "summary": "Agenus Inc. director Garo H. Armen received a grant of 4,852 shares of common stock on July 10, 2026, as compensation for his salary in lieu of cash. The shares, valued at $3.35 each, are fully vested and were issued under the company's 2019 Equity Incentive plan. Following this ", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-8168078c57b3.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:39:39", "published_display": "14 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "From \u201cMost Promising\u201d to Phase 3: Up to $340M to Advance BOT/BAL in MSS Colon Cancer", "summary": "Agenus has secured up to $340 million in a private placement to fund a registrational Phase 3 trial (ROBBIN) of its combination therapy BOT/BAL for microsatellite-stable (MSS) colon cancer. This financing follows two years of promising clinical data, including durable survival ra", "url": "https://oncodaily.com/oncolibrary/gastrointestinal-oncology/bot-bal-agenus", "source_name": "Oncodaily", "published_at": "2026-07-14T17:39:39", "published_display": "14 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGEN Stock Pulls Back After Huge Spike As Traders Dig Into Financials", "summary": "Agenus Inc. (AGEN) stock experienced a significant pullback after a recent price surge, prompting traders to scrutinize its financials. While the company shows strong revenue growth, its balance sheet reveals weak liquidity with negative equity and working capital. The article hi", "url": "https://stockstotrade.com/news/agenus-inc-agen-news-2026_07_14/", "source_name": "StocksToTrade", "published_at": "2026-07-14T17:03:00", "published_display": "14 Jul 2026 17:03", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Agenus Stock Falling on Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQTXFtaVJMRGdwbHg0MC1yQmhRU0RraUE4Zmg2QWhKTFZXRW9CRDgxTFBuZV84YjlQUWRXN2Y2WlhSWTJwcnhVMHNrSWp2M1JrOENuRjEyZnJFTG5tbnJWSDNxeWZ4Nmo5Ym5xVGxxVFpsbVhpN2hOM1UzbXV4YkRNaEc3emFCaTRqbF9mVFZPdU5QZ1pPM2FyZWNlSkgtdVFR?oc=5", "source_name": "Benzinga", "published_at": "2026-07-14T15:37:37+00:00", "published_display": "14 Jul 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot", "summary": "Agenus (AGEN) shares surged nearly 83% after securing an oversubscribed private placement of up to $340 million. This financing is intended to fund a strategic pivot towards a registrational Phase III study for colon cancer, extending the company\u2019s cash runway through 2031 if war", "url": "https://www.tradingview.com/news/zacks:ffdab7a8f094b:0-agen-stock-jumps-on-securing-340m-financing-to-fund-strategic-pivot/", "source_name": "TradingView", "published_at": "2026-07-14T15:39:39", "published_display": "14 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer", "summary": "Agenus Inc. has halted financial support for its phase 3 BATTMAN trial evaluating botensilimab plus balstilimab (BOT+BAL) in late-line metastatic microsatellite-stable (MSS) colorectal cancer. This decision is driven by a strategic shift to prioritize the planned phase 3 ROBBIN t", "url": "https://www.cancernetwork.com/view/agenus-discontinues-phase-3-battman-trial-metastatic-mss-colorectal-cancer", "source_name": "CancerNetwork", "published_at": "2026-07-14T15:39:39", "published_display": "14 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus stock doubles as biotech narrows Phase 3 bet", "summary": "", "url": "https://finance.yahoo.com/m/ed91a50c-27a5-34e8-a68b-5d5405db272f/agenus-stock-doubles-as.html", "source_name": "TheStreet", "published_at": "2026-07-14T14:17:00+00:00", "published_display": "14 Jul 2026 14:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPVnZWWUlwMC1sOFBwanNnNW11MmlydXBlQ0h2UmlsSGE5TjhLbTlwZzBSR2ZHUWwxYjdCRzRfc1FWazFrN2FrSGdPZEgzQjg3MWdMaENKYllfR0NFMHVDT21MbU5PdXRPWXJUbkoya1R4dGRBZ3ZIcTg0OFhZX3J5VFNpNE5nS0dvU0FNc3Zrb0c?oc=5", "source_name": "Market source", "published_at": "2026-07-14T12:15:00+00:00", "published_display": "14 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/agenus-agen-74-9-durable-101527901.html", "source_name": "Simply Wall St.", "published_at": "2026-07-14T10:15:27+00:00", "published_display": "14 Jul 2026 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer - Slideshow (NASDAQ:AGEN) 2026-07-14", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNa0Nqc0tlaC1UVkdqdWJIUURXQVpGdTZTWkM0dFpxYmFIVVpabmFWU3N0YXFkbjQ5MFJwWm1nQnZ3TXRpN0ZvSThCNTNmUExyZmNzZHVuUU1oVGd5NEhvNXVPc3hLaDBLZWlBd3ltaU80V3lQVW4xdV9WTlV5RU5RNlF6amJqMmg0elJtSzdoY1VfMUZaV2NXeTNxR053MGhZelRabUtJbE1vODJFMzJuR2tKTUVMMElSUHk5ZzFvX3ZwYlB6N1hIRVUyR2k5UGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T05:39:24+00:00", "published_display": "14 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus raises up to $340M to fund Phase 3 trial for colon cancer immunotherapy.", "summary": "Agenus Inc. has secured up to $340 million through an oversubscribed private placement to finance a Phase 3 trial for its immunotherapy combination BOT+BAL, targeting microsatellite-stable colon cancer. The ROBBIN trial aims to enroll 850 patients globally, with initial dosing in", "url": "https://pluang.com/en/news-feed/agenus-melonjak-dan-dapatkan-pendanaan-340juta-untuk-uji-kanker-usus", "source_name": "Pluang", "published_at": "2026-07-14T06:13:42", "published_display": "14 Jul 2026 06:13", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus shares surge as company secures up to $340M to advance colon cancer trial", "summary": "Agenus shares surged by approximately 100% after the company secured up to $340 million through an oversubscribed private placement to fund its ROBBIN Phase 3 trial. This trial will evaluate the BOT+BAL immunotherapy combination for microsatellite-stable (MSS) colon cancer. The f", "url": "https://finance.yahoo.com/healthcare/articles/agenus-shares-surge-company-secures-165300383.html", "source_name": "Market source", "published_at": "2026-07-14T01:39:39", "published_display": "14 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Investor update Summary", "summary": "Agenus is focusing its efforts on neoadjuvant BOT/BAL for high-risk Stage II/III MSS colon cancer, supported by strong clinical data and a planned Phase 3 trial. The company secured up to $340 million in financing to fund the ROBBIN Phase 3 trial and operations through 2031, targ", "url": "https://quartr.com/events/agenus-inc-agen-investor-update_oqyqkw7o", "source_name": "Quartr", "published_at": "2026-07-14T01:10:04", "published_display": "14 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Secures Up to $340M to Advance ROBBIN and Prioritize Neoadjuvant BOT/BAL in MSS Colon Cancer", "summary": "Agenus Inc. has secured up to $340 million through an oversubscribed private placement to advance its Phase 3 ROBBIN trial, evaluating neoadjuvant botensilimab plus balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing allows Agenus to prioritize the R", "url": "https://oncodaily.com/oncolibrary/gastrointestinal-oncology/agenus-2", "source_name": "Oncodaily", "published_at": "2026-07-13T20:10:04", "published_display": "13 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Agenus stock price target to $30 on strategy shift", "summary": "H.C. Wainwright has increased its price target for Agenus Inc. from $23 to $30, maintaining a Buy rating, following the biotech company's strategic shift in developing bot/bal for neoadjuvant MSS-CRC. The firm updated its financial model assuming a 2030 launch and anticipates $2.", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-agenus-stock-price-target-to-30-on-strategy-shift-93CH-4789024", "source_name": "Investing.com", "published_at": "2026-07-13T17:10:04", "published_display": "13 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Agenus Stock Gaining Monday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWVJPN1ZjenNtRWM2cVhjbmM0VDVsSlRVaHJHRkZ3MDRscFlZWF90Q25ZMWtMQm9oVmc3cEJwQkM0VFN0MUZmUW8zRXNpaUF1RE9oRElidWY3a0hmU2Y2ZXVzN0pUblJvVDJIUVpBa3FxbkdqUTJKWmlFbW10bUl1Ui0zbVdPbl85d05tUkxxZ0QzTm5BUXc?oc=5", "source_name": "Benzinga", "published_at": "2026-07-13T15:29:26+00:00", "published_display": "13 Jul 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQa0JvNjBrdC12bVZvS1lCYjB0MHhXQjBXbG5qT1ZaSS1ZN3VPcDFhRzVrSFBJc0ZHeTlvcDBaak5JOWJVQWtuUDRRX0ktSHJHY0tyMDFTc3BQM0JIbnF3M0ZBdlVJTjZOcFNjUDJneHAtMjVzX3VReDF2Z19YM2NjT2w3aHByaGctZkRiMWFLRFhUeGNvaUlOM3BSQzdPLWRSV3k3MkxkTERuZmF5VnFXLXpRX1FwRnRMY2lwcjdiMU1oakcwNEE?oc=5", "source_name": "Benzinga", "published_at": "2026-07-13T14:28:42+00:00", "published_display": "13 Jul 2026 14:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing", "summary": "", "url": "https://finance.yahoo.com/m/6fce3826-d2b6-3803-aabc-f9c1c5382770/agenus-pivots-to-phase-3.html", "source_name": "MarketBeat", "published_at": "2026-07-13T14:02:46+00:00", "published_display": "13 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ:AGEN) Stock Rockets 59% Premarket\u2014But Its $340 Million Lifeline Could Nearly Triple the Share Count", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPeVBjcW94ek9PdlVxTExZOXpTNmdvcVBlUG5hSHhSVDZxbGtnWjB6REFobFppTmtETktSVkNCTEl2RUU0QWFoaFlyV1M3Z1lEMThQdXVFRVhsWXR3LW15SzZzNmxCazB3UE9uMEFtLXE0aHM1M3FGVjJSUzl1U014NVQtYVJYWngwXzJNZm50OU16d09jZ1ZQdDZ1aUdZZXdkWW1yQkZkSnRnbU95eXlhenlfVnpGMWhhWjQtRUhyWEdpdldPcS1PQjZB?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-13T13:44:33+00:00", "published_display": "13 Jul 2026 13:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQNjg0aG84RlROQkMxc2xNcjdoMnRHRU10OUplb3dwbzJkOFZVcEJJWXdxT0NrUkVQdDdKTUtTOW9iOW9zTFltbllDNV9Pd0VTb01FMWUwam5fWkhpaVJZaEFrTHVLM19ocDlSUUFaNGVFZTR5VGVObXlzY1RDQ0xCSlVwR2I2d0Y5Y29UcHptSDJ0NFpVYzln?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:25:37+00:00", "published_display": "13 Jul 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus surges on study pivot; Apnimed lines up an IPO", "summary": "", "url": "https://finance.yahoo.com/m/cbce1547-db0d-351c-9d37-3aea2f25281b/agenus-surges-on-study-pivot%3B.html", "source_name": "BioPharma Dive", "published_at": "2026-07-13T11:46:02+00:00", "published_display": "13 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Secures Up to $340 Million to Advance Phase 3 Colon Cancer Trial", "summary": "Agenus Inc. has secured up to $340 million through an oversubscribed private placement to fund the late-stage development of its immunotherapy combination, botensilimab and balstilimab (BOT+BAL), for high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. This ", "url": "https://www.citybiz.co/article/872925/agenus-secures-up-to-340-million-to-advance-phase-3-colon-cancer-trial/", "source_name": "citybiz", "published_at": "2026-07-13T12:31:42", "published_display": "13 Jul 2026 12:31", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus rises premarket; Micron, Western Digital slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPYUhwX1YzbzBhb01aUVJVZGFOb2NYdnFVSHRad3pNMXZlTWtFRERrZWZySWxZOEZ0SjlRWHlqcVdpRDAxYlhEbEVoVUNEQXV0MW1XVDdGM0JTcHlkcFlfbHUzZWdWVGZlX25pX2R4U0tURDV4NGdUQUh1OFdrbmwxWU9LcnhUbS1zRmZ6eHNHQ19JM3lndkxoODNvdHVKN1Vuc1RfeWZHanJXVU1D?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T10:36:40+00:00", "published_display": "13 Jul 2026 10:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus stock jumps on $85 million private placement financing", "summary": "Agenus Inc. (NASDAQ:AGEN) shares rose 13% in premarket trading after announcing an $85 million private placement, with a potential total of $340 million upon full warrant exercise. The funds will support its ROBBIN Phase 3 trial, extending its cash runway through 2031, while the ", "url": "https://m.investing.com/news/stock-market-news/agenus-stock-jumps-on-85-million-private-placement-financing-93CH-4787807?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T10:41:42", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 80, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] AGENUS INC Reports Material Event", "summary": "Agenus Inc. has filed an 8-K report detailing a securities purchase agreement for a private placement expected to close on July 15, 2026. This financing, totaling up to $340 million, will fund the strategic prioritization of botensilimab and balstilimab (BOT+BAL) for neoadjuvant ", "url": "https://www.stocktitan.net/sec-filings/AGEN/8-k-agenus-inc-reports-material-event-89d64bcf5da8.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:41:42", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Raises $85 Million in Private Placement, Warrants Could Add $255 Million More", "summary": "Agenus announced a private placement that is expected to raise approximately $85 million in gross proceeds. Additionally, Series A and Series B warrants could generate up to an extra $255 million if fully exercised, with the closing anticipated on July 15, 2026. The funds will be", "url": "https://www.tradingview.com/news/tradingview:0bd4b0decfd6e:0-agenus-raises-85-million-in-private-placement-warrants-could-add-255-million-more/", "source_name": "TradingView", "published_at": "2026-07-13T10:41:42", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer", "summary": "Agenus Inc. has announced an oversubscribed private placement of up to $340 million to fund its registrational Phase 3 ROBBIN trial for neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing includes $85 million upfront and ", "url": "https://www.businesswire.com/news/home/20260713089967/en/Agenus-Announces-Oversubscribed-Private-Placement-of-Up-to-%24340-Million-to-Advance-Registrational-ROBBIN-Trial-of-Neoadjuvant-BOTBAL-in-MSS-Colon-Cancer", "source_name": "Business Wire", "published_at": "2026-07-13T09:41:42", "published_display": "13 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Wright of Agenus (NASDAQ: AGEN) granted deferred stock units", "summary": "Agenus director Timothy Wright was granted 2,267.765 Deferred Stock Units on July 1, 2026, as routine compensation. These units, valued at $3.583 each based on the prior quarter's average closing price, are tied to the company's common stock and will typically be settled in share", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-283ccd0ae5b6.html", "source_name": "Stock Titan", "published_at": "2026-07-07T15:10:48", "published_display": "07 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ: AGEN) director Harrison awarded 8,547 shares as board compensation", "summary": "Agenus (NASDAQ: AGEN) director Thomas L. Harrison was awarded 8,547 shares of common stock on July 1, 2026, as board compensation. These shares were acquired under the company\u2019s Board Compensation Election Policy, allowing directors to receive fees in stock. This grant increased ", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-29e4e491567f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T15:10:48", "published_display": "07 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Agenus Inc For: 7 July By Investing.com", "summary": "This article reports that a Form 4 filing for Agenus Inc. was made on July 7th. It includes the stock symbol AGEN and its current price performance, showing a 2.64% increase. The article itself is very brief, mainly serving as a notification about the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-4-agenus-inc-for-7-july-93CH-2589419", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T14:39:16", "published_display": "07 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI", "summary": "Agenus announced three-year overall survival data for its botensilimab (BOT) and balstilimab (BAL) combination therapy in refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The Phase 1b data, presented at ESMO GI 2026, show", "url": "https://oncodaily.com/oncolibrary/gastrointestinal-oncology/agenus-536086", "source_name": "Oncodaily", "published_at": "2026-07-07T12:09:25", "published_display": "07 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Achieves 33% Three-Year Survival in Colorectal Cancer", "summary": "Agenus Inc. reported promising three-year overall survival data for botensilimab in refractory microsatellite-stable (MSS) metastatic colorectal cancer, with 33% of patients alive at 36 months \u2013 a significant improvement over historical outcomes in this challenging disease. While", "url": "https://allsci.com/news/clinical-trials/agenus-posts-three-year-survival-data-for-botensilimab-in-mss-colorectal-cancer/", "source_name": "AllSci", "published_at": "2026-07-06T23:15:08", "published_display": "06 Jul 2026 23:15", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ: AGEN) extends note maturity and long-dated warrants", "summary": "Agenus Inc. (NASDAQ: AGEN) has extended the maturity date of $5.09 million in senior subordinated promissory notes from June 20, 2026, to February 18, 2027. Additionally, the company extended the expiration dates of three series of existing warrants covering 165,000 shares of com", "url": "https://www.stocktitan.net/sec-filings/AGEN/8-k-agenus-inc-reports-material-event-1a32148536e0.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:41:03", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Extends $5.09M Notes to 2027, Lengthens Warrants to 2031 and Issues New D Warrants", "summary": "Agenus has extended $5.09 million in 2015 senior subordinated notes to February 18, 2027, maintaining existing terms. The company also prolonged the expiration dates of its 2022 A and B Warrants and 2025 C Warrants to June 25, 2031, and issued new 2026 D Warrants for 56,525 share", "url": "https://www.tradingview.com/news/tradingview:238309ee5f288:0-agenus-extends-5-09m-notes-to-2027-lengthens-warrants-to-2031-and-issues-new-d-warrants/", "source_name": "TradingView", "published_at": "2026-07-06T20:41:03", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus BOT+BAL Shows 33% Three-Year Survival in Immunotherapy-Resistant Colorectal Cancer", "summary": "Agenus announced that its BOT+BAL combination therapy achieved a 33% three-year overall survival rate in patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC) without active liver metastases. This data, to be presented at ESMO GI 2026, demonstrate", "url": "https://www.biopharminternational.com/view/agenus-bot-bal-shows-33-three-year-survival-in-immunotherapy-resistant-colorectal-cancer", "source_name": "BioPharm International", "published_at": "2026-07-06T18:41:03", "published_display": "06 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus reports 3-year survival data in colorectal cancer study", "summary": "Agenus reported positive 3-year Phase 1b data for its botensilimab and balstilimab combination in metastatic colorectal cancer, showing a median overall survival of 21.2 months and a 33% 3-year overall survival rate. The study observed no new safety signals and 98% resolution of ", "url": "https://grafa.com/en/news/united-states/agenus-botensilimab-balstilimab-3-year-survival-data", "source_name": "grafa.com", "published_at": "2026-07-06T15:41:04", "published_display": "06 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares", "summary": "Agenus Inc. director Dr. Garo H. Armen opted to receive his June 2026 salary in 5,364 shares of company common stock, valued at $3.03 per share, instead of cash. These shares were fully vested upon issuance under the company's 2019 Equity Incentive plan, bringing his direct holdi", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-4ec929302df9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:10:47", "published_display": "30 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Agenus Inc For: 30 June By Investing.com", "summary": "This article provides a Form 4 filing for Agenus Inc. as of June 30. It is a brief financial update published by Investing.com. The information indicates an insider transaction or change in beneficial ownership for the specified date.", "url": "https://ca.investing.com/news/stock-market-news/form-4-agenus-inc-for-30-june-93CH-4713294", "source_name": "Investing.com Canada", "published_at": "2026-06-30T10:10:47", "published_display": "30 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ: AGEN) investors approve equity plan changes and KPMG", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQYWpkUThiTUFvaHpwMld3UTRkTFR0SFI4TmV2RUxkcjhub3o0aU8xWlVLZ1BmWDAzUjNrRU1KbkNFOWE1WmpneTUwaDZfVXFBTXdkQy0zeXlqeGp4cXROQzZ2U3NibjdFVmQxMGpEaEpKcnl5R0UtdkUyOHRYMVg4eHVCN1NxNjZ5bzdfNi16WjNSSVJXQmo5MEhsSDFybDY2?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPanI5WloyaFJlbS1KU2NLRXhkWEtCOW0yTEpQNWR0VVpJQ0hiX3I5ZEpjWjJzbHlqRUY0TFZycFFuT1c0RV9FTmJPRVN0Zlg4TE1XRXFEclJNcDR1ZkgxWVR0dGQ5UGVoTmNEaXhxQnVUSTdvUE1CbWN3RkJMQW40aW9RQmoyX05CdTlYeVNpbGcxOEZE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Agenus Stock a Hold Amid Valuation and Funding Risks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQQlAxY011OEN2bnBqbGdMRnM3SFZUQ2hJay1pLWNWeldBTHdyOUhBd0k3VVlGMW1Db0JOam5qRUhoNGE1bEc3SmdXRzNuS3dId1Z0QTlxMFJ1eGlXZHB5NE1zYU1MTmctSmVnUk5jOWJhYmpvUFh5SDRFS1cwQXBWc1JaT1ZIYThxU3MtWWhQY1ltdlllUUk4YmxCMmlXdw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxNR3R4MkdRbHczT1pOR1Q1VUUtODZ2ZFNlMTZvcWIyMS1PU2V3RXpSaF93emNhLXdBN0plZUtlUmU4NTd6V25zams1UzdSVE1adlJpYU1ValVUdUxYbTNCa01GZVlBcEd5SjU2T3lLQkt3b2VYSGxFaG9HMzdBYzZVV0N6RXAxZEY5T2F6aUVybFNmSjVqMkhGd3NDQmFUQ3NWZENyVURYRUc4eVFka2VIVF9kV2N1NVkxUWx6RnVRSDNncDZrUl9MTzhkLThiVTc5MlpBbHE5bm1zMHNlTFZDVGJ2YlNJM3NfcjFMM3gtRkE0RjdaeTVfZmZlakozLVlNZGRkcldhZXlORGxzOS0wN1NOVQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxPTmJYZEtab051R01aOVNkRG45bEVwd2xHTTE0VWltcGlNQ1M4OHhaZ2ZqcEFEVDFKNGJKZEtKc3EyWEZyNWNxR2VZdnFvaXJfYXV6R0hJbGRpT3VEWHBZN0xhd2hQR2JHWGg5RzdxRUtpWUxwMWZqcERRUjdlT1dlOGhYc1p4YnpXblpLbUcwNEtNTlp3VXdhU29Vb2p1RHg4NFFyZUVBMEI2Yy1TU2ZtWTdiaFYtR282LVpCOWlXck9fRE80MXQ3dlBnNEVWOHdOeFpGeDZVVGhtcUlTTFVKbDJXSUhiWlJqbUxqSjhmcVpxWVJTczVNMkZWWkhGVnpKY2NYUnlpODFlV2VNZW54UVBuWDFVSWQ3T01zRk56WXBRTXRJOHpGSHBB?oc=5", "source_name": "Business Wire", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxOVjEzVXAzN29INmlJYWJwWXF2RnpxOTFYakQ5cmVIZUhudkVYeDFoVHdDZHQ5VHRtRW9KVEtWUUc0blpYSy1VT0otV2pVT2dCTUxUMVpLQjJSeVJKOFFzS2xmOEtkRDNDLUxiTHY4YTNUQkFJUkdDOGJJRzdKa1NQU3RUaWZydHFpOGMxZHpYeWtoNGlhbW0wclo5aHJzNlBvVzNFRWpJUXFkWjZwSjBFZ3NTQWxRUlRlT3FMNmgzTE8yUjN5MlVlSmplZ3pFR3ZzZlBhOXJJbEt5V0JoMk00VWltdkowTmQwUnhoYUU4MGNhR09LcXFxT1h3?oc=5", "source_name": "scanx.trade", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus and Zydus transactions face new CFIUS review, closing shifts to Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOelNGRE9weHEwZDhKWkhZNHFHWUpRUklvVUQ2RHRiWU82cW9GcUtfRHJkSHprTWRJWnREaGlJemR4R1NIck5GSEFXbDFUZUZ2T3JMNlM5R3cycGVaM1Q1SjFyXzZnLUVnU0hscW4wZVhIVVhGcFppMkNpVkc1cGlMaGZUR2c3NTIxRFhBbllremJWdjZaWEYxYWRfa0JKclJHb3JQZFdlYXkxLURLUkZpTWNtMk1mY0Q3RERHOTN0U3B5cUVtWHBV?oc=5", "source_name": "Investing.com", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE5FdnpjWVF6aTNncE1zR2V6QzBCMzZwcDBjWlNSYWdMWWdqZjZqUkNnZzh6cWFEVlpLdDZWa2VnaFpETldWcEU2eHpscDRiTHBBeHRTcGZLSktoRG9tTUNuRXRUR0J2S21DLWtUeC13LXZ6d1E?oc=5", "source_name": "Oncodaily", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T13:37:29+00:00", "published_display": "15 Jul 2026 13:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Surges 83% On $340 Million Financing: The Road To A 2030 Breakthrough (NASDAQ:AGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxPTkRWSVFKZTJFRnhHaEhWbXc0NEpYaDRsZ25vckViQ09sSEQtSXc1bnRyUnY2bVo2M055SmlDdGV4UUhDTFBNN2RyY1B2ZzlvUWV1V2V3dFVtYlBaQkdtUUI4LVpWVjBoa0dJZFpPY0dieTBiVmNEVUZmTVVrd2VCZTNoUENPbk1RVjNEZ1pDOV96WlQwTjhJM0hubEJ1OWtWa2xESnZIZU8?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T12:04:17+00:00", "published_display": "15 Jul 2026 12:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Inc. (NASDAQ: AGEN) director takes 4,852-share stock salary grant", "summary": "Agenus Inc. director Garo H. Armen received a grant of 4,852 shares of common stock on July 10, 2026, as compensation for his salary in lieu of cash. The shares, valued at $3.35 each, are fully vested and were issued under the company's 2019 Equity Incentive plan. Following this ", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-8168078c57b3.html", "source_name": "Stock Titan", "published_at": "2026-07-14T19:39:39", "published_display": "14 Jul 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "From \u201cMost Promising\u201d to Phase 3: Up to $340M to Advance BOT/BAL in MSS Colon Cancer", "summary": "Agenus has secured up to $340 million in a private placement to fund a registrational Phase 3 trial (ROBBIN) of its combination therapy BOT/BAL for microsatellite-stable (MSS) colon cancer. This financing follows two years of promising clinical data, including durable survival ra", "url": "https://oncodaily.com/oncolibrary/gastrointestinal-oncology/bot-bal-agenus", "source_name": "Oncodaily", "published_at": "2026-07-14T17:39:39", "published_display": "14 Jul 2026 17:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGEN Stock Pulls Back After Huge Spike As Traders Dig Into Financials", "summary": "Agenus Inc. (AGEN) stock experienced a significant pullback after a recent price surge, prompting traders to scrutinize its financials. While the company shows strong revenue growth, its balance sheet reveals weak liquidity with negative equity and working capital. The article hi", "url": "https://stockstotrade.com/news/agenus-inc-agen-news-2026_07_14/", "source_name": "StocksToTrade", "published_at": "2026-07-14T17:03:00", "published_display": "14 Jul 2026 17:03", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Agenus Stock Falling on Tuesday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQTXFtaVJMRGdwbHg0MC1yQmhRU0RraUE4Zmg2QWhKTFZXRW9CRDgxTFBuZV84YjlQUWRXN2Y2WlhSWTJwcnhVMHNrSWp2M1JrOENuRjEyZnJFTG5tbnJWSDNxeWZ4Nmo5Ym5xVGxxVFpsbVhpN2hOM1UzbXV4YkRNaEc3emFCaTRqbF9mVFZPdU5QZ1pPM2FyZWNlSkgtdVFR?oc=5", "source_name": "Benzinga", "published_at": "2026-07-14T15:37:37+00:00", "published_display": "14 Jul 2026 15:37", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot", "summary": "Agenus (AGEN) shares surged nearly 83% after securing an oversubscribed private placement of up to $340 million. This financing is intended to fund a strategic pivot towards a registrational Phase III study for colon cancer, extending the company\u2019s cash runway through 2031 if war", "url": "https://www.tradingview.com/news/zacks:ffdab7a8f094b:0-agen-stock-jumps-on-securing-340m-financing-to-fund-strategic-pivot/", "source_name": "TradingView", "published_at": "2026-07-14T15:39:39", "published_display": "14 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Discontinues Phase 3 BATTMAN Trial in Metastatic MSS Colorectal Cancer", "summary": "Agenus Inc. has halted financial support for its phase 3 BATTMAN trial evaluating botensilimab plus balstilimab (BOT+BAL) in late-line metastatic microsatellite-stable (MSS) colorectal cancer. This decision is driven by a strategic shift to prioritize the planned phase 3 ROBBIN t", "url": "https://www.cancernetwork.com/view/agenus-discontinues-phase-3-battman-trial-metastatic-mss-colorectal-cancer", "source_name": "CancerNetwork", "published_at": "2026-07-14T15:39:39", "published_display": "14 Jul 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus stock doubles as biotech narrows Phase 3 bet", "summary": "", "url": "https://finance.yahoo.com/m/ed91a50c-27a5-34e8-a68b-5d5405db272f/agenus-stock-doubles-as.html", "source_name": "TheStreet", "published_at": "2026-07-14T14:17:00+00:00", "published_display": "14 Jul 2026 14:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxPVnZWWUlwMC1sOFBwanNnNW11MmlydXBlQ0h2UmlsSGE5TjhLbTlwZzBSR2ZHUWwxYjdCRzRfc1FWazFrN2FrSGdPZEgzQjg3MWdMaENKYllfR0NFMHVDT21MbU5PdXRPWXJUbkoya1R4dGRBZ3ZIcTg0OFhZX3J5VFNpNE5nS0dvU0FNc3Zrb0c?oc=5", "source_name": "Market source", "published_at": "2026-07-14T12:15:00+00:00", "published_display": "14 Jul 2026 12:15", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Is Up 74.9% After Durable Botensilimab Combo Data In Refractory Colorectal Cancer - Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/agenus-agen-74-9-durable-101527901.html", "source_name": "Simply Wall St.", "published_at": "2026-07-14T10:15:27+00:00", "published_display": "14 Jul 2026 10:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Inc. (AGEN) Discusses Financing and Robin Trial Strategy for Neoadjuvant Immunotherapy in MSS Colon Cancer - Slideshow (NASDAQ:AGEN) 2026-07-14", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNa0Nqc0tlaC1UVkdqdWJIUURXQVpGdTZTWkM0dFpxYmFIVVpabmFWU3N0YXFkbjQ5MFJwWm1nQnZ3TXRpN0ZvSThCNTNmUExyZmNzZHVuUU1oVGd5NEhvNXVPc3hLaDBLZWlBd3ltaU80V3lQVW4xdV9WTlV5RU5RNlF6amJqMmg0elJtSzdoY1VfMUZaV2NXeTNxR053MGhZelRabUtJbE1vODJFMzJuR2tKTUVMMElSUHk5ZzFvX3ZwYlB6N1hIRVUyR2k5UGc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T05:39:24+00:00", "published_display": "14 Jul 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus raises up to $340M to fund Phase 3 trial for colon cancer immunotherapy.", "summary": "Agenus Inc. has secured up to $340 million through an oversubscribed private placement to finance a Phase 3 trial for its immunotherapy combination BOT+BAL, targeting microsatellite-stable colon cancer. The ROBBIN trial aims to enroll 850 patients globally, with initial dosing in", "url": "https://pluang.com/en/news-feed/agenus-melonjak-dan-dapatkan-pendanaan-340juta-untuk-uji-kanker-usus", "source_name": "Pluang", "published_at": "2026-07-14T06:13:42", "published_display": "14 Jul 2026 06:13", "sentiment": "positive", "sentiment_pct": 90, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus shares surge as company secures up to $340M to advance colon cancer trial", "summary": "Agenus shares surged by approximately 100% after the company secured up to $340 million through an oversubscribed private placement to fund its ROBBIN Phase 3 trial. This trial will evaluate the BOT+BAL immunotherapy combination for microsatellite-stable (MSS) colon cancer. The f", "url": "https://finance.yahoo.com/healthcare/articles/agenus-shares-surge-company-secures-165300383.html", "source_name": "Market source", "published_at": "2026-07-14T01:39:39", "published_display": "14 Jul 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Investor update Summary", "summary": "Agenus is focusing its efforts on neoadjuvant BOT/BAL for high-risk Stage II/III MSS colon cancer, supported by strong clinical data and a planned Phase 3 trial. The company secured up to $340 million in financing to fund the ROBBIN Phase 3 trial and operations through 2031, targ", "url": "https://quartr.com/events/agenus-inc-agen-investor-update_oqyqkw7o", "source_name": "Quartr", "published_at": "2026-07-14T01:10:04", "published_display": "14 Jul 2026 01:10", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Secures Up to $340M to Advance ROBBIN and Prioritize Neoadjuvant BOT/BAL in MSS Colon Cancer", "summary": "Agenus Inc. has secured up to $340 million through an oversubscribed private placement to advance its Phase 3 ROBBIN trial, evaluating neoadjuvant botensilimab plus balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing allows Agenus to prioritize the R", "url": "https://oncodaily.com/oncolibrary/gastrointestinal-oncology/agenus-2", "source_name": "Oncodaily", "published_at": "2026-07-13T20:10:04", "published_display": "13 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright raises Agenus stock price target to $30 on strategy shift", "summary": "H.C. Wainwright has increased its price target for Agenus Inc. from $23 to $30, maintaining a Buy rating, following the biotech company's strategic shift in developing bot/bal for neoadjuvant MSS-CRC. The firm updated its financial model assuming a 2030 launch and anticipates $2.", "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-agenus-stock-price-target-to-30-on-strategy-shift-93CH-4789024", "source_name": "Investing.com", "published_at": "2026-07-13T17:10:04", "published_display": "13 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Agenus Stock Gaining Monday?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOWVJPN1ZjenNtRWM2cVhjbmM0VDVsSlRVaHJHRkZ3MDRscFlZWF90Q25ZMWtMQm9oVmc3cEJwQkM0VFN0MUZmUW8zRXNpaUF1RE9oRElidWY3a0hmU2Y2ZXVzN0pUblJvVDJIUVpBa3FxbkdqUTJKWmlFbW10bUl1Ui0zbVdPbl85d05tUkxxZ0QzTm5BUXc?oc=5", "source_name": "Benzinga", "published_at": "2026-07-13T15:29:26+00:00", "published_display": "13 Jul 2026 15:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Stock Soars Over 100% as BATTMAN Takes a Back Seat to ROBBIN", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQa0JvNjBrdC12bVZvS1lCYjB0MHhXQjBXbG5qT1ZaSS1ZN3VPcDFhRzVrSFBJc0ZHeTlvcDBaak5JOWJVQWtuUDRRX0ktSHJHY0tyMDFTc3BQM0JIbnF3M0ZBdlVJTjZOcFNjUDJneHAtMjVzX3VReDF2Z19YM2NjT2w3aHByaGctZkRiMWFLRFhUeGNvaUlOM3BSQzdPLWRSV3k3MkxkTERuZmF5VnFXLXpRX1FwRnRMY2lwcjdiMU1oakcwNEE?oc=5", "source_name": "Benzinga", "published_at": "2026-07-13T14:28:42+00:00", "published_display": "13 Jul 2026 14:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing", "summary": "", "url": "https://finance.yahoo.com/m/6fce3826-d2b6-3803-aabc-f9c1c5382770/agenus-pivots-to-phase-3.html", "source_name": "MarketBeat", "published_at": "2026-07-13T14:02:46+00:00", "published_display": "13 Jul 2026 14:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ:AGEN) Stock Rockets 59% Premarket\u2014But Its $340 Million Lifeline Could Nearly Triple the Share Count", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPeVBjcW94ek9PdlVxTExZOXpTNmdvcVBlUG5hSHhSVDZxbGtnWjB6REFobFppTmtETktSVkNCTEl2RUU0QWFoaFlyV1M3Z1lEMThQdXVFRVhsWXR3LW15SzZzNmxCazB3UE9uMEFtLXE0aHM1M3FGVjJSUzl1U014NVQtYVJYWngwXzJNZm50OU16d09jZ1ZQdDZ1aUdZZXdkWW1yQkZkSnRnbU95eXlhenlfVnpGMWhhWjQtRUhyWEdpdldPcS1PQjZB?oc=5", "source_name": "TechStock\u00b2", "published_at": "2026-07-13T13:44:33+00:00", "published_display": "13 Jul 2026 13:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQNjg0aG84RlROQkMxc2xNcjdoMnRHRU10OUplb3dwbzJkOFZVcEJJWXdxT0NrUkVQdDdKTUtTOW9iOW9zTFltbllDNV9Pd0VTb01FMWUwam5fWkhpaVJZaEFrTHVLM19ocDlSUUFaNGVFZTR5VGVObXlzY1RDQ0xCSlVwR2I2d0Y5Y29UcHptSDJ0NFpVYzln?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:25:37+00:00", "published_display": "13 Jul 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus surges on study pivot; Apnimed lines up an IPO", "summary": "", "url": "https://finance.yahoo.com/m/cbce1547-db0d-351c-9d37-3aea2f25281b/agenus-surges-on-study-pivot%3B.html", "source_name": "BioPharma Dive", "published_at": "2026-07-13T11:46:02+00:00", "published_display": "13 Jul 2026 11:46", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Secures Up to $340 Million to Advance Phase 3 Colon Cancer Trial", "summary": "Agenus Inc. has secured up to $340 million through an oversubscribed private placement to fund the late-stage development of its immunotherapy combination, botensilimab and balstilimab (BOT+BAL), for high-risk Stage II and Stage III microsatellite-stable (MSS) colon cancer. This ", "url": "https://www.citybiz.co/article/872925/agenus-secures-up-to-340-million-to-advance-phase-3-colon-cancer-trial/", "source_name": "citybiz", "published_at": "2026-07-13T12:31:42", "published_display": "13 Jul 2026 12:31", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus rises premarket; Micron, Western Digital slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPYUhwX1YzbzBhb01aUVJVZGFOb2NYdnFVSHRad3pNMXZlTWtFRERrZWZySWxZOEZ0SjlRWHlqcVdpRDAxYlhEbEVoVUNEQXV0MW1XVDdGM0JTcHlkcFlfbHUzZWdWVGZlX25pX2R4U0tURDV4NGdUQUh1OFdrbmwxWU9LcnhUbS1zRmZ6eHNHQ19JM3lndkxoODNvdHVKN1Vuc1RfeWZHanJXVU1D?oc=5", "source_name": "Investing.com", "published_at": "2026-07-13T10:36:40+00:00", "published_display": "13 Jul 2026 10:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus stock jumps on $85 million private placement financing", "summary": "Agenus Inc. (NASDAQ:AGEN) shares rose 13% in premarket trading after announcing an $85 million private placement, with a potential total of $340 million upon full warrant exercise. The funds will support its ROBBIN Phase 3 trial, extending its cash runway through 2031, while the ", "url": "https://m.investing.com/news/stock-market-news/agenus-stock-jumps-on-85-million-private-placement-financing-93CH-4787807?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-13T10:41:42", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 80, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] AGENUS INC Reports Material Event", "summary": "Agenus Inc. has filed an 8-K report detailing a securities purchase agreement for a private placement expected to close on July 15, 2026. This financing, totaling up to $340 million, will fund the strategic prioritization of botensilimab and balstilimab (BOT+BAL) for neoadjuvant ", "url": "https://www.stocktitan.net/sec-filings/AGEN/8-k-agenus-inc-reports-material-event-89d64bcf5da8.html", "source_name": "Stock Titan", "published_at": "2026-07-13T10:41:42", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Raises $85 Million in Private Placement, Warrants Could Add $255 Million More", "summary": "Agenus announced a private placement that is expected to raise approximately $85 million in gross proceeds. Additionally, Series A and Series B warrants could generate up to an extra $255 million if fully exercised, with the closing anticipated on July 15, 2026. The funds will be", "url": "https://www.tradingview.com/news/tradingview:0bd4b0decfd6e:0-agenus-raises-85-million-in-private-placement-warrants-could-add-255-million-more/", "source_name": "TradingView", "published_at": "2026-07-13T10:41:42", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer", "summary": "Agenus Inc. has announced an oversubscribed private placement of up to $340 million to fund its registrational Phase 3 ROBBIN trial for neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer. This financing includes $85 million upfront and ", "url": "https://www.businesswire.com/news/home/20260713089967/en/Agenus-Announces-Oversubscribed-Private-Placement-of-Up-to-%24340-Million-to-Advance-Registrational-ROBBIN-Trial-of-Neoadjuvant-BOTBAL-in-MSS-Colon-Cancer", "source_name": "Business Wire", "published_at": "2026-07-13T09:41:42", "published_display": "13 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director Wright of Agenus (NASDAQ: AGEN) granted deferred stock units", "summary": "Agenus director Timothy Wright was granted 2,267.765 Deferred Stock Units on July 1, 2026, as routine compensation. These units, valued at $3.583 each based on the prior quarter's average closing price, are tied to the company's common stock and will typically be settled in share", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-283ccd0ae5b6.html", "source_name": "Stock Titan", "published_at": "2026-07-07T15:10:48", "published_display": "07 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ: AGEN) director Harrison awarded 8,547 shares as board compensation", "summary": "Agenus (NASDAQ: AGEN) director Thomas L. Harrison was awarded 8,547 shares of common stock on July 1, 2026, as board compensation. These shares were acquired under the company\u2019s Board Compensation Election Policy, allowing directors to receive fees in stock. This grant increased ", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-29e4e491567f.html", "source_name": "Stock Titan", "published_at": "2026-07-07T15:10:48", "published_display": "07 Jul 2026 15:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Agenus Inc For: 7 July By Investing.com", "summary": "This article reports that a Form 4 filing for Agenus Inc. was made on July 7th. It includes the stock symbol AGEN and its current price performance, showing a 2.64% increase. The article itself is very brief, mainly serving as a notification about the regulatory filing.", "url": "https://ng.investing.com/news/stock-market-news/form-4-agenus-inc-for-7-july-93CH-2589419", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T14:39:16", "published_display": "07 Jul 2026 14:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI", "summary": "Agenus announced three-year overall survival data for its botensilimab (BOT) and balstilimab (BAL) combination therapy in refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases. The Phase 1b data, presented at ESMO GI 2026, show", "url": "https://oncodaily.com/oncolibrary/gastrointestinal-oncology/agenus-536086", "source_name": "Oncodaily", "published_at": "2026-07-07T12:09:25", "published_display": "07 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Achieves 33% Three-Year Survival in Colorectal Cancer", "summary": "Agenus Inc. reported promising three-year overall survival data for botensilimab in refractory microsatellite-stable (MSS) metastatic colorectal cancer, with 33% of patients alive at 36 months \u2013 a significant improvement over historical outcomes in this challenging disease. While", "url": "https://allsci.com/news/clinical-trials/agenus-posts-three-year-survival-data-for-botensilimab-in-mss-colorectal-cancer/", "source_name": "AllSci", "published_at": "2026-07-06T23:15:08", "published_display": "06 Jul 2026 23:15", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ: AGEN) extends note maturity and long-dated warrants", "summary": "Agenus Inc. (NASDAQ: AGEN) has extended the maturity date of $5.09 million in senior subordinated promissory notes from June 20, 2026, to February 18, 2027. Additionally, the company extended the expiration dates of three series of existing warrants covering 165,000 shares of com", "url": "https://www.stocktitan.net/sec-filings/AGEN/8-k-agenus-inc-reports-material-event-1a32148536e0.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:41:03", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Extends $5.09M Notes to 2027, Lengthens Warrants to 2031 and Issues New D Warrants", "summary": "Agenus has extended $5.09 million in 2015 senior subordinated notes to February 18, 2027, maintaining existing terms. The company also prolonged the expiration dates of its 2022 A and B Warrants and 2025 C Warrants to June 25, 2031, and issued new 2026 D Warrants for 56,525 share", "url": "https://www.tradingview.com/news/tradingview:238309ee5f288:0-agenus-extends-5-09m-notes-to-2027-lengthens-warrants-to-2031-and-issues-new-d-warrants/", "source_name": "TradingView", "published_at": "2026-07-06T20:41:03", "published_display": "06 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus BOT+BAL Shows 33% Three-Year Survival in Immunotherapy-Resistant Colorectal Cancer", "summary": "Agenus announced that its BOT+BAL combination therapy achieved a 33% three-year overall survival rate in patients with refractory microsatellite-stable metastatic colorectal cancer (MSS mCRC) without active liver metastases. This data, to be presented at ESMO GI 2026, demonstrate", "url": "https://www.biopharminternational.com/view/agenus-bot-bal-shows-33-three-year-survival-in-immunotherapy-resistant-colorectal-cancer", "source_name": "BioPharm International", "published_at": "2026-07-06T18:41:03", "published_display": "06 Jul 2026 18:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus reports 3-year survival data in colorectal cancer study", "summary": "Agenus reported positive 3-year Phase 1b data for its botensilimab and balstilimab combination in metastatic colorectal cancer, showing a median overall survival of 21.2 months and a 33% 3-year overall survival rate. The study observed no new safety signals and 98% resolution of ", "url": "https://grafa.com/en/news/united-states/agenus-botensilimab-balstilimab-3-year-survival-data", "source_name": "grafa.com", "published_at": "2026-07-06T15:41:04", "published_display": "06 Jul 2026 15:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares", "summary": "Agenus Inc. director Dr. Garo H. Armen opted to receive his June 2026 salary in 5,364 shares of company common stock, valued at $3.03 per share, instead of cash. These shares were fully vested upon issuance under the company's 2019 Equity Incentive plan, bringing his direct holdi", "url": "https://www.stocktitan.net/sec-filings/AGEN/form-4-agenus-inc-insider-trading-activity-4ec929302df9.html", "source_name": "Stock Titan", "published_at": "2026-06-30T10:10:47", "published_display": "30 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Agenus Inc For: 30 June By Investing.com", "summary": "This article provides a Form 4 filing for Agenus Inc. as of June 30. It is a brief financial update published by Investing.com. The information indicates an insider transaction or change in beneficial ownership for the specified date.", "url": "https://ca.investing.com/news/stock-market-news/form-4-agenus-inc-for-30-june-93CH-4713294", "source_name": "Investing.com Canada", "published_at": "2026-06-30T10:10:47", "published_display": "30 Jun 2026 10:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (NASDAQ: AGEN) investors approve equity plan changes and KPMG", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQYWpkUThiTUFvaHpwMld3UTRkTFR0SFI4TmV2RUxkcjhub3o0aU8xWlVLZ1BmWDAzUjNrRU1KbkNFOWE1WmpneTUwaDZfVXFBTXdkQy0zeXlqeGp4cXROQzZ2U3NibjdFVmQxMGpEaEpKcnl5R0UtdkUyOHRYMVg4eHVCN1NxNjZ5bzdfNi16WjNSSVJXQmo5MEhsSDFybDY2?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPanI5WloyaFJlbS1KU2NLRXhkWEtCOW0yTEpQNWR0VVpJQ0hiX3I5ZEpjWjJzbHlqRUY0TFZycFFuT1c0RV9FTmJPRVN0Zlg4TE1XRXFEclJNcDR1ZkgxWVR0dGQ5UGVoTmNEaXhxQnVUSTdvUE1CbWN3RkJMQW40aW9RQmoyX05CdTlYeVNpbGcxOEZE?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Agenus Stock a Hold Amid Valuation and Funding Risks?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQQlAxY011OEN2bnBqbGdMRnM3SFZUQ2hJay1pLWNWeldBTHdyOUhBd0k3VVlGMW1Db0JOam5qRUhoNGE1bEc3SmdXRzNuS3dId1Z0QTlxMFJ1eGlXZHB5NE1zYU1MTmctSmVnUk5jOWJhYmpvUFh5SDRFS1cwQXBWc1JaT1ZIYThxU3MtWWhQY1ltdlllUUk4YmxCMmlXdw?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwJBVV95cUxNR3R4MkdRbHczT1pOR1Q1VUUtODZ2ZFNlMTZvcWIyMS1PU2V3RXpSaF93emNhLXdBN0plZUtlUmU4NTd6V25zams1UzdSVE1adlJpYU1ValVUdUxYbTNCa01GZVlBcEd5SjU2T3lLQkt3b2VYSGxFaG9HMzdBYzZVV0N6RXAxZEY5T2F6aUVybFNmSjVqMkhGd3NDQmFUQ3NWZENyVURYRUc4eVFka2VIVF9kV2N1NVkxUWx6RnVRSDNncDZrUl9MTzhkLThiVTc5MlpBbHE5bm1zMHNlTFZDVGJ2YlNJM3NfcjFMM3gtRkE0RjdaeTVfZmZlakozLVlNZGRkcldhZXlORGxzOS0wN1NOVQ?oc=5", "source_name": "Business Wire", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus (AGEN) Q3 Profit Of US$63.9 Million Tests Longstanding Loss-Making Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgJBVV95cUxPTmJYZEtab051R01aOVNkRG45bEVwd2xHTTE0VWltcGlNQ1M4OHhaZ2ZqcEFEVDFKNGJKZEtKc3EyWEZyNWNxR2VZdnFvaXJfYXV6R0hJbGRpT3VEWHBZN0xhd2hQR2JHWGg5RzdxRUtpWUxwMWZqcERRUjdlT1dlOGhYc1p4YnpXblpLbUcwNEtNTlp3VXdhU29Vb2p1RHg4NFFyZUVBMEI2Yy1TU2ZtWTdiaFYtR282LVpCOWlXck9fRE80MXQ3dlBnNEVWOHdOeFpGeDZVVGhtcUlTTFVKbDJXSUhiWlJqbUxqSjhmcVpxWVJTczVNMkZWWkhGVnpKY2NYUnlpODFlV2VNZW54UVBuWDFVSWQ3T01zRk56WXBRTXRJOHpGSHBB?oc=5", "source_name": "Business Wire", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zydus Lifesciences Completes Agenus Acquisition, Establishes Zylidac Bio LLC for US Biologics Manufacturing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-gFBVV95cUxOVjEzVXAzN29INmlJYWJwWXF2RnpxOTFYakQ5cmVIZUhudkVYeDFoVHdDZHQ5VHRtRW9KVEtWUUc0blpYSy1VT0otV2pVT2dCTUxUMVpLQjJSeVJKOFFzS2xmOEtkRDNDLUxiTHY4YTNUQkFJUkdDOGJJRzdKa1NQU3RUaWZydHFpOGMxZHpYeWtoNGlhbW0wclo5aHJzNlBvVzNFRWpJUXFkWjZwSjBFZ3NTQWxRUlRlT3FMNmgzTE8yUjN5MlVlSmplZ3pFR3ZzZlBhOXJJbEt5V0JoMk00VWltdkowTmQwUnhoYUU4MGNhR09LcXFxT1h3?oc=5", "source_name": "scanx.trade", "published_at": "2026-01-15T08:00:00+00:00", "published_display": "15 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus and Zydus transactions face new CFIUS review, closing shifts to Q4", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOelNGRE9weHEwZDhKWkhZNHFHWUpRUklvVUQ2RHRiWU82cW9GcUtfRHJkSHprTWRJWnREaGlJemR4R1NIck5GSEFXbDFUZUZ2T3JMNlM5R3cycGVaM1Q1SjFyXzZnLUVnU0hscW4wZVhIVVhGcFppMkNpVkc1cGlMaGZUR2c3NTIxRFhBbllremJWdjZaWEYxYWRfa0JKclJHb3JQZFdlYXkxLURLUkZpTWNtMk1mY0Q3RERHOTN0U3B5cUVtWHBV?oc=5", "source_name": "Investing.com", "published_at": "2025-09-23T07:00:00+00:00", "published_display": "23 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE5FdnpjWVF6aTNncE1zR2V6QzBCMzZwcDBjWlNSYWdMWWdqZjZqUkNnZzh6cWFEVlpLdDZWa2VnaFpETldWcEU2eHpscDRiTHBBeHRTcGZLSktoRG9tTUNuRXRUR0J2S21DLWtUeC13LXZ6d1E?oc=5", "source_name": "Oncodaily", "published_at": "2025-06-10T07:00:00+00:00", "published_display": "10 Jun 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 57, "sentiment_summary": {"positive": 20, "negative": 3, "neutral": 34, "score": 58, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 84, "events": [{"event": "general", "label": "Market update", "weight": 21.6, "count": 38}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 11}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 3.35, "latest_week": "2026-07-10", "one_week_move": -4.0, "four_week_move": 1.5, "twelve_week_move": -30.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.447391, "market_dynamics_buy_signal": false, "relative_strength": -25.914716, "fair_value_gap": -59.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.1078, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.0% over one week, +1.5% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 4}, {"label": "Oncodaily", "count": 4}, {"label": "TradingView", "count": 4}, {"label": "Investing.com", "count": 4}, {"label": "Benzinga", "count": 3}, {"label": "Business Wire", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 38}, {"label": "Earnings", "count": 11}, {"label": "Balance sheet", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "84/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.0% over one week, +1.5% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Agenus (AGEN) Could Be 83% Undervalued On Phase 1b Data And $340 Million Raise"}], "updated_at": "2026-07-16T00:49:49.507921+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}